Predictive Accuracy of HeartMate 3 Risk Score After the Heart Transplant Allocation Change.
| Autor: | Vincent JD; From the Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri., Ramsay A; Division of Cardiac Surgery, Massachusetts General Hospital, Boston, Massachusetts., Lambert DS; From the Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri., Deych E; Division of Cardiology, Washington University School of Medicine, Saint Louis, Missouri., Pico AM; Division of Cardiac Surgery, Massachusetts General Hospital, Boston, Massachusetts., Coglianese E; Division of Cardiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts., Vader JM; From the Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri., Yang BQ; Division of Cardiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ASAIO journal (American Society for Artificial Internal Organs : 1992) [ASAIO J] 2024 Nov 06. Date of Electronic Publication: 2024 Nov 06. |
| DOI: | 10.1097/MAT.0000000000002343 |
| Abstrakt: | The HeartMate 3 risk score (HM3RS) was developed from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) clinical trial to predict 1 and 2 year mortality after left ventricular assist device implantation. However, it has not been validated in a real-world population, especially after the heart transplant allocation system change on October 18, 2018. In this multicenter retrospective analysis, we found that HM3RS did not predict 1 and 2 year outcomes in the contemporary era, highlighting the need to revise this risk prediction tool in the real-world setting. Competing Interests: Disclosure: The authors have no conflicts of interest to report. (Copyright © ASAIO 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|